Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation

Mayo Clinic125 enrolled

Overview

The purpose of this study is to determine biomarkers which can predict response to ablation therapy in patients with Barretts esophagus.

This Project is designed to identify biologically-based and clinically-useful biomarkers of tissue at risk for neoplastic progression as well as of response to ablation therapy. These results will result in improved risk stratification in BE and better targeting of resources for patients who are candidates for ablative therapy, while simultaneously providing key information regarding the origins of Barrett's esophagus.

Study Type

OBSERVATIONAL

Enrollment

125

Conditions

Barrett's Esophagus

Interventions

response to therapyGENETIC

evaluate specific markers for response to therapy at specific intervals pre and post therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Barrett's esophagus with high grade dysplasia or intramucosal (early) adenocarcinoma. * BE length ≥ 2 cm and ≤ 8 cm. * Able to return every 3 months for one year after ablation Exclusion Criteria: * Patients who are unable to be compliant with follow-up endoscopies * patients who cannot tolerate Proton Pump inhibitors * pre-existing esophageal strictures * pregnant or nursing women

Locations (2)

Columbia University

New York, New York, United States

University of Pennsylvania Perelman School of Medicine

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Response to therapy

evaulation will be made at 3 month intervals for one year post ablation

Time frame: one year post ablation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.